Identification of appropriate patients for cardiometabolic risk management

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 4, 2007, Pages

  Peters, Anne L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cardiovascular disease risk; Diabetes; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Waist circumference

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETES MELLITUS; DYSLIPIDEMIA; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FUNCTION; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; REVIEW; RISK REDUCTION; WAIST CIRCUMFERENCE;

AGE FACTORS; CARDIOVASCULAR DISEASES; DIABETES, GESTATIONAL; DYSLIPIDEMIAS; FATTY LIVER; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MOTOR ACTIVITY; OBESITY; PATIENT SELECTION; POLYCYSTIC OVARY SYNDROME; PRACTICE GUIDELINES; PREGNANCY; RISK ASSESSMENT; RISK FACTORS;

EID: 35348874750     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718-723.
2. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
3. National Heart, Lung, and Blood Institute. Framingham Heart Study. Available at: www.nhlbi.nih.gov/about/framingham/index.html. Accessed May 7, 2006.
4. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care. 2005;28:2289-2304.
5. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
6. American Diabetes Association. Diabetes PHD: Personal health decisions. Available at: www.diabetes.org/diabetesphd/default.jsp?WTLPromo=HOME_PHD. Accessed May 7, 2006.
7. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the UK. Diabetes Care. 2006;29:798-804.
8. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
9. Cho E, Rimm EB, Stampfer MJ, et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002;40:954-960.
10. American Diabetes Association. Standards of Medical Care in Diabetes-2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
11. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk. Arch Intern Med. 2002;162:2074-2079.
12. Seidell JC, Perusse L, Despres JP, Bouchard C Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr. 2001;74:315-321.
13. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8:605-619.
14. Maison P, Byrne CD, Hales CN, et al. Do different dimensions of the metabolic syndrome change together over time? Diabetes Care. 2001;24:1758-1763.
15. Haffner SM, D'Agostino R, Festa A, et al. Low insulin sensitivity (Si = 0) in diabetic and non-diabetic subjects in the Insulin Resistance Atherosclerosis Study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care. 2003;26:2796-2803.
16. Zhu S, Heymsfield SB, Toyoshima H, et al. Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am J Clin Nutr. 2005;81:409-415.
17. Zhu S, Wang Z, Heshka S, et al. Waist circumference and obesity-associated risk factors among whites in the Third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr. 2002;76:743-749.
18. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6(suppl 2):S51-S210.
19. National Health and Nutrition Examination Survey. Anthropometry Procedures Manual. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2000. Available at: www.cdc.gov/nchs/data/nhanes/bm.pdf. Accessed April 29, 2006.
20. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158-161.
21. Okosun IS, Liao Y, Rotimi CN, et al. Predictive values of waist circumference for dyslipidemia, type 2 diabetes and hypertension in overweight white, black, and Hispanic American adults. J Clin Epidemiol. 2000;53:401-408.
22. Ardern CI, Janssen I, Ross R, Katzmarzyk PT. Development of health-related waist circumference thresholds within BMI categories. Obes Res. 2004;12:1094-1103.
23. Harris TB, Visser M, Everhart J, et al. Waist circumference and sagittal diameter reflect total body fat better than visceral fat in older men and women. The Health, Aging and Body Composition Study. Ann NY Acad Sci. 2000;904:462-473.
24. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182-1186.
25. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat percent relationship. Obes Rev. 2002;3:141-146.
26. Regional Office for the Western Pacific, World Health Organization, International Association for the Study of Obesity, and the International Obesity Task Force. Asia-Pacific perspective: redefining obesity and its treatment. Available at: www.idi.org.au/home.htm. Accessed May 7, 2006.
27. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens. 2004;22:1845-1847.
28. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27:247-255.
29. Hypertension in Diabetes Study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;1:309-317.
30. Garcia Puig J, Ruilope LM, Luque Otero M, Bobadilla JF. Prevalence of carbohydrate metabolic alterations in hospital based hypertension units in Spain: the AVANT study [abstract]. J Hypertens. 2004;22(suppl 1):S97.
31. Zavaroni I, Mazza S, Dall'Aglio E, et al. Prevalence of hyperinsulinemia in patients with high blood pressure. J Intern Med. 1992;231:235-240.
32. D'Agostino RB Jr, Hamman RF, Karter AJ, et al. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:2234-2240.
33. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144.
34. Benjamin SM, Valdez R, Geiss LS, et al. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care. 2003;26:645-649.
35. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
36. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
37. American Diabetes Association. Diabetes risk test. Available at: www.diabetes.org/risk-test.jsp. Accessed May 24, 2006.
38. Björnholt J, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999;22:45-49.
39. Meigs JB, Nathan DM, Wilson PW, et al. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med. 1998;128:524-533.
40. Lim SC, Tai ES, Tan BY, et al. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization provisional report. Diabetes Care. 2000;23:278-282.
41. Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25:1990-1997.
42. Aguilar D, Solomon SD, Kober L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004;110:1572-1578.
43. Kernan WN, Viscoli CM, Inzucchi SE, et al. Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med. 2005;165:227-233.
44. Stern MP, Fatehi P, Williams K, Haffner SM. Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care. 2002;25:1851-1856.
45. Davidson MB, Schriger DL, Peters AL, Lorber B. Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. J Gen Intern Med. 2000;15:551-555.
46. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
47. Solano MP, Goldberg RB. Management of dyslipidemia in diabetes. Cardiol Rev. 2006;14:125-135.
48. Laaksonen DE, Hanna-Maaria L, Jukka TS, et al. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care. 2002;25:1612-1618.
49. Stern SE, Williams K, Ferrannini E, et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes. 2005;54:333-339.
50. Tang W, Hong Y, Province MA, et al. Familial clustering for features of the metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes Care. 2006;29:631-636.
51. Scuteri A, Najjar SS, Morrell CH, Lakatta EG. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. The Cardiovascular Health Study. Diabetes Care. 2005;28:882-887.
52. Sartor B, Dickey RP. Polycystic ovarian syndrome and the metabolic syndrome. Am J Med Sci. 2005;330:336-342.
53. Carmina E, Legro RS, Stamets K, et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod. 2003;18:2289-2293.
54. Legro RS, Kunselman AR, Dodson WE, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-169.
55. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-146.
56. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908-915.
57. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821-826.
58. Elting MW, Dorsen TJM, Bezemer PD, et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16:556-560.
59. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983;61:403-407.
60. Apridonidze T, Essah P, Luorno M, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929-1935.
61. Lobner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes. 2006;55:792-797.
62. Noussitou P, Monbaron D, Vial Y, et al. Gestational diabetes mellitus and the risk of metabolic syndrome: a population-based study in Lausanne, Switzerland. Diabetes Metab. 2005;31:361-369.
63. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121.
64. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67:575-583.
65. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335.
66. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79.
67. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis. 2004;8:549-558.
68. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 2000;26:98-106.
69. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:1849-1855.
70. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967.
71. de Ferranti SD, Gauvreau K, Ludwig DS, et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004;110:2494-2497.
72. Braunschweig CL, Gomez S, Liang H, et al. Obesity and risk factors for the metabolic syndrome among low-income, urban, African American schoolchildren: the rule rather than the exception? Am J Clin Nutr. 2005;81:970-975.
73. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320:1240-1243.
74. International Diabetes Federation. The IDF Consensus worldwide definition of the metabolic syndrome. Available at: www.idf.org.Accessed June 2, 2005.